Author

Fatih M. Uckun

President, Ares Pharmaceutical LLC and Executive Medical Director, Global Oncology and hematology at - Cited by 32,554 - Cancer Research - Translational Oncology - Clinical Strategy
Title
Cited by
Year
Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug
FM Uckun, S Saund, H Windlass, V TrieuFrontiers in Pharmacology 12, 407, 2021202
33
2021
Antibody responses to COVID-19 vaccination in cancer: a systematic review
DC Guven, TK Sahin, S Kilickap, FM UckunFrontiers in Oncology 11, 759108, 2021202
30
2021
COVID-19 pandemic: changes in cancer admissions
DC Guven, BY Aktas, MS Aksun, E Ucgul, TK Sahin, HC Yildirim, G Guner, ...BMJ supportive & palliative care, 2020202
30
2020
Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long …
FM Uckun, S Qazi, L Hwang, VN TrieuCancers 11 (12), 1892, 2019201
26
2019
Overcoming the immunosuppressive tumor microenvironment in multiple myeloma
FM UckunCancers 13 (9), 2018, 2021202
26
2021
Clinical impact potential of supplemental nutrients as adjuncts of therapy in high-risk COVID-19 for obese patients
E Sahin, C Orhan, FM Uckun, K SahinFrontiers in nutrition 7, 580504, 2020202
24
2020
Reducing the fatality rate of COVID-19 by applying clinical insights from immuno-oncology and lung transplantation
FM UckunFrontiers in pharmacology 11, 796, 2020202
21
2020
Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model …
FM Uckun, J Carlson, C Orhan, J Powell, NM Pizzimenti, H van Wyk, ...Frontiers in Pharmacology, 1682,
20
2020
A phase 1B clinical study of combretastatin A1 diphosphate (OXi4503) and cytarabine (ARA-C) in combination (OXA) for patients with relapsed or refractory acute myeloid leukemia
FM Uckun, CR Cogle, TL Lin, S Qazi, VN Trieu, G Schiller, JM WattsCancers 12 (1), 74, 202
19
2019
A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
FM Uckun, TL Lin, AS Mims, P Patel, C Lee, A Shahidzadeh, PJ Shami, ...Cancers 13 (16), 4113, 2021202
15
2021
Impact of therapy in patients with hematologic malignancies on seroconversion rates after SARS-CoV-2 vaccination
DC Guven, TK Sahin, S Akın, FM UckunThe Oncologist 27 (4), e357-e361, 2022202
12
2022
Targeting TGF-β pathway with COVID-19 drug candidate ARTIVeda/PulmoHeal accelerates recovery from mild-moderate COVID-19
V Trieu, S Saund, PV Rahate, VB Barge, KS Nalk, H Windlass, FM UckunMedRxiv, 2021.01. 24.21250418, 2021202
11
2021
Targeting solid tumors with BTK inhibitors
FM Uckun, T VenkatachalamFrontiers in Cell and Developmental Biology , 650414, 2021202
9
2021
Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma
FM UckunFrontiers in Oncology 11, 76032, 2021202
8
2021
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or …
CR Cogle, B Collins, D Turner, LC Pettiford, R Bossé, KE Hawkins, ...British journal of haematology 19 (5), e211-e213, 2020202
8
2020
Prognostic factors associated with high-risk for fatal ARDS in COVID-19 and potential role for precision Medicines as part of COVID-19 supportive care algorithms
FM UckunAnn. Pulm. Crit. Care Med 3 (2), 1-4, 2020202
5
2020
Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases
K Sahin, M Yabas, C Orhan, M Tuzcu, TK Sahin, IH Ozercan, S Qazi, ...Expert Opinion on Therapeutic Targets 24 (4), 379-387, 2020202
5
2020
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61
TK Sahin, OH Aktepe, FM Uckun, S YalcinAnti-Cancer Drugs 31 (6), 609-616, 2020202
5
2020
Risk, characteristics and biomarkers of cytokine release syndrome in patients with relapsed/refractory AML or MDS treated with CD3xCD123 bispecific antibody APVO436
Risk, characteristics and biomarkers of cytokine release syndrome in patients with relapsed/refractory AML or MDS treated with CD3xCD123 bispecific antibody APVO36FM Uckun, J Watts, AS Mims, P Patel, E Wang, PJ Shami, E Cull, C Lee, ...Cancers 13 (21), 5287, 2021202
4
2021
CD123-directed bispecific antibodies for targeting MDS clones and immunosuppressive myeloid-derived suppressor cells (MDSC) in high-risk adult MDS patients
CD12-directed bispecific antibodies for targeting MDS clones and immunosuppressive myeloid-derived suppressor cells (MDSC) in high-risk adult MDS patientsFM Uckun, J WattsFrontiers in Aging 2, 757276, 2021202
3
2021

Referred From: https://scholar.google.com/citations?user=-qftQHQAAAAJ&hl=en

Cited by
Citations 32554
h-index 93
i10-index 546
Recommended Journals
Open Access Journals